Another trial found no benefit from ivermectin for COVID symptoms

A new study has poured one last bucket of cold water on the idea of ​​using ivermectin to treat COVID-19.

Dr Adrian Hernandez, executive director of the Duke University Clinical Research Institute in Durham, said: “There was no significant benefit in our primary endpoint for addressing symptoms in COVID-19 disease- 19 mild to moderate or any other criteria”. NC

“With these results, and combined with an earlier arm of research that tested a different dose of ivermectinivermectin does not appear to have any role in the treatment of mild to moderate COVID-19, especially when considering other available options with its proven ability to reduce hospitalizations and deaths.” he said in a Duke press release.

Researchers from Duke and Vanderbilt Universities in Nashville, Tenn., randomly selected more than 1,300 participants to take either ivermectin 600 mcg/kg daily or a placebo for six days, starting last February.

The previous trial tested a single dose of ivermectin 400 mcg/kg daily for three days from June 2021 to February 2022 and found no clinically significant benefit for symptoms, hospitalization, or to the emergency room.

This latest study found no difference in mild-to-moderate symptoms between patients taking the placebo and those taking the higher dose.

“Public interest in ivermectin and its favorable safety profile supported its trial,” said Dr. Susanna Naggie, Duke’s principal investigator overseeing the study’s clinical coordination center. in this study to assess the benefits and risks rigorously.

Although ivermectin is approved to treat parasitic infections, the US Food and Drug Administration has not approved it to treat COVID-19.

The latest findings have been submitted to a peer-reviewed journal.